Laboratory researchers have wide-ranging competences in order to make development of complex radiopharmaceuticals and radioisotopes for medical purposes. At the moment there has been considerable research on development of new radiopharmaceuticals based on beta-emitters for therapy in Oncology on the basis of rhenium-186, rhenium-188, yttrium-90, phosphorus-32 and others.
Laboratory No. 31 conducts the history since 2003. Currently, she directs the Ph. D. Nesterov Evgeniy Aleksandrovich. 80% of the laboratory staff has scientific degrees of candidates and doctors of Sciences. School of nuclear technology TPU on the basis of the nuclear reactor IRT-T for more than 20 years of operational laboratory No. 31. Scientists of the laboratory № 31 together with domestic and foreign physicians and scientists implementing research projects on the development of technologies for the creation of radiopharmaceutical medicinal products and medical devices used in cardiology, Oncology, endocrinology, pulmonology and other fields of medicine. Also conducted theoretical and experimental research in the field of nuclear and radiation physics, radiation technologies for medicine and industry.
On the basis of laboratory No. 31, in accordance with the requirements of good manufacturing practice GMP and the norms and rules of production of drugs organized non-waste manufacturing of generators technetium-99m for medical institutions of Russia, as well as radiopharmaceutical drugs (RFLP) with technetium-99m and thallium-199. Started the procedure for registration of drugs containing iodine-123. Created Production Department of radiopharmaceuticals, and quality control of radiopharmaceuticals, the departments are operating RFLP, on analytical, radiometric, microbiological, and other types of research. For the production of radiopharmaceuticals obtained all necessary permits and licenses, including the License of the Ministry, Rostekhnadzor, Rospotrebnadzor, the certifying body of ISO, etc.
Together with Tomsk national research medical center of RAS created a new and unique technologies for production and preclinical testing of new RFLP on the basis of the labeled with technetium-99m: doxorubicin for scintigraphic visualization of malignant tumors and prognosis of efficacy of chemotherapy, a derivative of glucose for radionuclide diagnostics of oncological diseases, gamma-aluminum oxide to lymphoscintigraphy, antibiotic-generation fluoroquinolone number for medical diagnosis of inflammation of octreotide for the diagnosis of neuroendocrine tumors, recombinant molecules for targeted radionuclide diagnostics of oncological diseases with overexpression of Her-2/neu, and on the basis of thallium-199 and diethyldithiocarbamate for the diagnosis of disorders of cerebral circulation and some others.